<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01185366</url>
  </required_header>
  <id_info>
    <org_study_id>2009-0628</org_study_id>
    <secondary_id>NCI-2012-01789</secondary_id>
    <nct_id>NCT01185366</nct_id>
  </id_info>
  <brief_title>Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma</brief_title>
  <official_title>Everolimus Versus Sunitinib Therapy in Patients With Advanced Non-clear Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to compare the effectiveness of Afinitor&#xD;
      (everolimus) and Sutent (sunitinib) for the treatment of advanced renal cell carcinoma&#xD;
      (kidney cancer). The safety of each treatment will also be studied.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Study Drugs:&#xD;
&#xD;
      Everolimus is designed to stop cells from multiplying. It may also stop the growth of new&#xD;
      blood vessels that help tumor growth, which may cause the tumor cells to die.&#xD;
&#xD;
      Sunitinib is designed to block pathways that control important events (such as the growth of&#xD;
      blood vessels) that are essential for the growth of cancer.&#xD;
&#xD;
      Study Groups and Study Drug Administration:&#xD;
&#xD;
      If you are found to be eligible to take part in this study, you will be randomly assigned (as&#xD;
      in the toss of a coin) to 1 of 2 groups.&#xD;
&#xD;
        -  If you are assigned to Group 1, you will take 2 everolimus tablets by mouth once every&#xD;
           day.&#xD;
&#xD;
        -  If you are assigned to Group 2, you will take sunitinib capsules by mouth every day for&#xD;
           4 weeks, followed by 2 weeks off.&#xD;
&#xD;
      If you have any side effects from any of the drugs, tell the study doctor right away. The&#xD;
      study doctor may then lower the dose or keep the dose level the same.&#xD;
&#xD;
      Every 6 weeks on this study is called a study &quot;cycle.&quot;&#xD;
&#xD;
      If the disease gets worse or you have intolerable side effects while you are on study, you&#xD;
      will have the chance to receive the study drug that you did not receive at first. The dosing&#xD;
      and follow-up will be the same as for all participants in that group.&#xD;
&#xD;
      Study Visits:&#xD;
&#xD;
      On Day 1 of every cycle:&#xD;
&#xD;
        -  You will have a physical exam, including measurement of your vital signs.&#xD;
&#xD;
        -  You will be asked about any drugs or treatments you may be receiving.&#xD;
&#xD;
        -  Your performance status will be recorded.&#xD;
&#xD;
        -  Blood (about 3 teaspoons) and urine will be collected for routine tests and a fasting&#xD;
           blood sugar test. Blood or urine will also be used for a pregnancy test for women who&#xD;
           are able to have children. If you are in Group 1, you will have an additional 1 teaspoon&#xD;
           of blood drawn to test your cholesterol.&#xD;
&#xD;
      On Day 15 and 29 of Cycle 1:&#xD;
&#xD;
        -  Your vital signs and weight will be measured.&#xD;
&#xD;
        -  Blood (about 2 teaspoons) will be drawn for routine tests. If you are in Group 1, an&#xD;
           additional 1 teaspoon of blood will be drawn to measure your cholesterol.&#xD;
&#xD;
      The Day 15 and Day 29 tests may be done at your local doctor's office.&#xD;
&#xD;
      On Day 1 of Cycles 2 and 3, and every other cycle after that (Day 1 of Cycle 5, 7, 9 and so&#xD;
      on):&#xD;
&#xD;
      °You will have a CT scan of the chest and a CT scan or MRI of the abdomen to check the status&#xD;
      of the disease.&#xD;
&#xD;
      Every 4 cycles (24 weeks):&#xD;
&#xD;
      °If you are in Group 2, you will have an echocardiogram or MUGA scan to check your heart's&#xD;
      health.&#xD;
&#xD;
      Length of Study:&#xD;
&#xD;
      You may continue taking the study drugs for as long as you are benefiting. You will be taken&#xD;
      off study if the disease gets worse or intolerable side effects occur.&#xD;
&#xD;
      End-of-Treatment Visit:&#xD;
&#xD;
      If you have stopped taking the study drug because of intolerable side effects, the treating&#xD;
      physician will make every effort to check the status of the disease before you are taken off&#xD;
      of study.&#xD;
&#xD;
      Long-Term Follow-up:&#xD;
&#xD;
      Once you are no longer on this study, the research staff will check up on you about every 6&#xD;
      months. This update will consist of a phone call or a review of your medical and/or other&#xD;
      records. You will not have any extra tests, procedures, or study visits. If contacted by&#xD;
      phone, the call would only last about 5 minutes.&#xD;
&#xD;
      This is an investigational study. Sunitinib and everolimus are both FDA approved and&#xD;
      commercially available for the treatment of advanced kidney cancer.&#xD;
&#xD;
      Up to 108 patients will be enrolled in this multicenter trial. Up to 108 patients will be&#xD;
      enrolled at MD Anderson.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">September 9, 2019</completion_date>
  <primary_completion_date type="Actual">September 9, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) for First Line Medication</measure>
    <time_frame>7 months</time_frame>
    <description>The amount of time after the first line medication begins until the cancer gets worse progresses. Progression is measured by an increase in measures tumors of at least 20 %, or overall increase in all the tumors, or the presence of new tumors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) for Crossover Medication</measure>
    <time_frame>4 months</time_frame>
    <description>The amount of time after the crossover medication begins until the cancer gets worse progresses. Progression is measured by an increase in measures tumors of at least 20 %, or overall increase in all the tumors, or the presence of new tumors.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced Either a Grade 3 or 4 Adverse Event</measure>
    <time_frame>1 year</time_frame>
    <description>Side effects, also called adverse events, that were related to either drug were documented and graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades increases in severity from 1 - 5. Grade one is a mild change which only requires monitoring. Grade 2 is a moderate change and may require some medication. Grade 3 is severe and requires hospitalization. Grade 4 is life threatening. Grade 5 is death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival of the First Line Therapy</measure>
    <time_frame>17 months</time_frame>
    <description>The amount of time each participant is alive from the start of the first line therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Best Overall Response for First Line Medication</measure>
    <time_frame>7 months</time_frame>
    <description>The best overall response for each participant was determined by using the Response Evaluation Criteria for Solid Tumors (RECIST). The responses are Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression Disease (PD). CR is the disappearance of the cancer everywhere in the participant. PR is at least a 30 % reduction in the measured tumors from baseline. SD is no discernible change in the presence of cancer. Progressive disease is an increase of at least 20% of the measured cancer from the cancer's smallest measure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">73</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>Everolimus Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Everolimus 10 mg by mouth once a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sunitinib Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sunitinib 50 mg by mouth daily for 4 weeks on / 2 weeks off.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>10 mg by mouth once a day.</description>
    <arm_group_label>Everolimus Group 1</arm_group_label>
    <other_name>Afinitor</other_name>
    <other_name>RAD001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sunitinib</intervention_name>
    <description>50 mg by mouth daily for 4 weeks on / 2 weeks off</description>
    <arm_group_label>Sunitinib Group 2</arm_group_label>
    <other_name>Sunitinib Malate</other_name>
    <other_name>SUO11248</other_name>
    <other_name>Sutent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must have advanced non-clear cell RCC, which may include but is not limited&#xD;
             to the following subtypes: papillary I or II, chromophobe, collecting duct carcinoma&#xD;
             (CDC), translocation or unclassified. Patients with conventional-type renal cell&#xD;
             carcinoma who have &gt;/= 20% sarcomatoid component in their primary tumor are eligible.&#xD;
             Patients who have sarcomatoid features in FNA or core biopsy of any metastatic site&#xD;
             are eligible, if they have an underlying renal cell carcinoma primary tumor.&#xD;
&#xD;
          2. Patients must have at least one measurable site of disease that has not been&#xD;
             previously irradiated. If the patient has had previous radiation to the marker&#xD;
             lesion(s), there must be evidence of progression since the radiation&#xD;
&#xD;
          3. ECOG performance status 0-1&#xD;
&#xD;
          4. Age &gt;/= 18 years&#xD;
&#xD;
          5. Patients must have adequate organ and marrow function within 14 days prior to study&#xD;
             entry as defined below: a) Hemoglobin &gt;/= 9 g/dl (tx allowed); b) absolute neutrophil&#xD;
             count &gt;/=1,500/microL; c) platelets &gt;/= 100,000/microL; d) total bilirubin &lt;/= 1.5&#xD;
             mg/dl; e) AST(SGOT) or ALT (SGPT) &lt;/=2.5 X institutional uln, except in known hepatic&#xD;
             metastasis, wherein may be &lt;/= 5 x ULN; f) Serum Creatinine &lt;/= 1.5 x ULN (as long as&#xD;
             patient does not require dialysis)&#xD;
&#xD;
          6. INR and PTT &lt;/= 1.5 x ULN within 14 days prior to study entry. Therapeutic&#xD;
             anticoagulation with warfarin is allowed if target INR &lt;/= 3 on a stable dose of&#xD;
             warfarin or on a stable dose of LMW heparin for &gt; 2 weeks (14 days) at time of&#xD;
             randomization.&#xD;
&#xD;
          7. Fasting serum cholesterol &lt;/= 300 mg/dL OR &lt;/= 7.75 mmol/L AND fasting triglycerides&#xD;
             &lt;/= 2.5 x ULN within 14 days prior to study entry.&#xD;
&#xD;
          8. Female patients of childbearing potential (not postmenopausal for at least 12 months&#xD;
             and not surgically sterile) must have a negative serum or urine pregnancy test within&#xD;
             14 days before study entry. Pregnancy test must be repeated if performed &gt; 14 days&#xD;
             before starting study drug.&#xD;
&#xD;
          9. Patients must give written informed consent prior to study entry, in keeping with the&#xD;
             policies of each institution.&#xD;
&#xD;
         10. Patients with a history of major psychiatric illness must be judged (by the treating&#xD;
             physician) able to fully understand the investigational nature of the study and the&#xD;
             risks associated with the therapy.&#xD;
&#xD;
         11. Patients with controlled brain metastases are allowed on protocol if they had solitary&#xD;
             brain metastases that was surgically resected or treated with radiosurgery or Gamma&#xD;
             knife, without recurrence or edema for 3 months (90days).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. No other malignancies within the past 2 years except for adequately treated carcinoma&#xD;
             of the cervix or basal (without recurrence post-surgery or post-radiotherapy) or&#xD;
             squamous cell carcinomas of the skin.&#xD;
&#xD;
          2. No prior systemic therapy for RCC including prior adjuvant therapy or investigational&#xD;
             drug is allowed.&#xD;
&#xD;
          3. Patients currently receiving anticancer therapies or who have received anticancer&#xD;
             therapies within 4 weeks (28 days) from enrollment into this study (including&#xD;
             chemotherapy and targeted therapy) are excluded. However, patients are permitted to&#xD;
             receive bisphosphonates. Also, patients who completed palliative radiation therapy&#xD;
             prior to enrollment in this trial are eligible.&#xD;
&#xD;
          4. Patients, who have had a major surgery or significant traumatic injury (injury&#xD;
             requiring &gt; 4 weeks (28 days) to heal) within 4 weeks (28 days) of start of study&#xD;
             drug, patients who have not recovered from the side effects of any major surgery&#xD;
             (defined as requiring general anesthesia) or patients that may require major surgery&#xD;
             during the course of the study.&#xD;
&#xD;
          5. Concomitant treatment with rifampin, St. John's wort, or the cytochrome p450&#xD;
             enzyme-inducing antiepileptic drugs (phenytoin, carbamazepine or Phenobarbital) or&#xD;
             CYP3A4 inhibitors is not recommended on this study.&#xD;
&#xD;
          6. Patients who have any severe and/or uncontrolled medical conditions or other&#xD;
             conditions that could affect their participation in the study such as: a) Symptomatic&#xD;
             congestive heart failure of New York heart Association Class III or IV; b) unstable&#xD;
             angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6&#xD;
             months of start of study drug, serious uncontrolled cardiac arrhythmia or any other&#xD;
             clinically significant cardiac disease; c) severely impaired lung function as defined&#xD;
             as 02 saturation that is 88% or less at rest on room air&#xD;
&#xD;
          7. (#6 cont'd) d) uncontrolled diabetes as defined by fasting serum glucose &gt;1.5 x ULN;&#xD;
             e) active (acute or chronic) or uncontrolled severe infections requiring antibiotic&#xD;
             intervention; f) liver disease such as cirrhosis, chronic active hepatitis or chronic&#xD;
             persistent hepatitis&#xD;
&#xD;
          8. Patients must not have history of other diseases, metabolic dysfunction, physical&#xD;
             examination finding, or clinical laboratory finding giving reasonable suspicion of a&#xD;
             disease or condition that contraindicates the use of sunitinib or everolimus or that&#xD;
             might affect the interpretation of the results of the study or render the subject at&#xD;
             high risk from treatment complications.&#xD;
&#xD;
          9. Concomitant treatment with drugs with dysrhythmic potential (terfenadine, quinidine,&#xD;
             procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, and&#xD;
             indapamide) is not recommended.&#xD;
&#xD;
         10. Patients receiving chronic, systemic treatment with corticosteroids or another&#xD;
             immunosuppressive agent. Topical or inhaled corticosteroids are allowed.&#xD;
&#xD;
         11. Patients should not receive immunization with attenuated live vaccines within one week&#xD;
             (7 days) of study entry or during study period.&#xD;
&#xD;
         12. Uncontrolled brain or leptomeningeal metastases, including patients who continue to&#xD;
             require glucocorticoids for brain or leptomeningeal metastases.&#xD;
&#xD;
         13. A known history of HIV sero-positivity.&#xD;
&#xD;
         14. Impairment of gastrointestinal function or gastrointestinal disease that may&#xD;
             significantly alter the absorption of everolimus and/or sunitinib (e.g., ulcerative&#xD;
             disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small&#xD;
             bowel resection).&#xD;
&#xD;
         15. Patients with an active, bleeding diathesis.&#xD;
&#xD;
         16. Female patients who are pregnant or breast feeding, or adults of reproductive&#xD;
             potential who are not using effective birth control methods. If barrier contraceptives&#xD;
             are being used, these must be continued throughout the trial by both sexes. Hormonal&#xD;
             contraceptives are not acceptable as a sole method of contraception. (Women of&#xD;
             childbearing potential must have a negative urine or serum pregnancy test within 7&#xD;
             days prior to study entry. Pregnancy test must be repeated if performed &gt; 7 days&#xD;
             before administration of everolimus and sunitinib)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amado Zurita, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute/Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute - University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 18, 2010</study_first_submitted>
  <study_first_submitted_qc>August 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2010</study_first_posted>
  <results_first_submitted>September 15, 2020</results_first_submitted>
  <results_first_submitted_qc>April 26, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 28, 2021</results_first_posted>
  <last_update_submitted>April 26, 2021</last_update_submitted>
  <last_update_submitted_qc>April 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced non-clear cell renal cell cancer (RCC)</keyword>
  <keyword>Clear-cell renal cell carcinoma</keyword>
  <keyword>Collecting duct carcinoma</keyword>
  <keyword>Translocation carcinoma</keyword>
  <keyword>Chromophobe</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Afinitor</keyword>
  <keyword>RAD001</keyword>
  <keyword>Sunitinib Malate</keyword>
  <keyword>SUO11248</keyword>
  <keyword>Sutent</keyword>
  <keyword>ESPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sunitinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT01185366/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>73 Participants recruited from August 2010 to November 2013 at MD Anderson and Dana-Farber/Harvard Cancer Center.</recruitment_details>
      <pre_assignment_details>73 participants were recruited, 1 Screen failure. 69 participants were evaluable. Eligible patients did not take systemic medication for advanced papillary, chromophobe, CDC, Xp11.2 translocation, unclassified RCC or ccRCC with ≥ 20% sarcomatoid features in their primary tumors.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Everolimus</title>
          <description>4 weeks of everolimus of 10 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to sunitinib.</description>
        </group>
        <group group_id="P2">
          <title>Sunitinib</title>
          <description>4 weeks of sunitinib of 50 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to everolimus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Line Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="38"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received 1st Drug</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Insurance Coverage Denied</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Metastatic Site</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Crossover to Second Line Therapy</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Crossover Drug</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Continued with 1st drug</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Everolimus</title>
          <description>4 weeks of everolimus of 10 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to sunitinib.</description>
        </group>
        <group group_id="B2">
          <title>Sunitinib</title>
          <description>4 weeks of sunitinib of 50 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to everolimus.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" lower_limit="23" upper_limit="73"/>
                    <measurement group_id="B2" value="60" lower_limit="28" upper_limit="76"/>
                    <measurement group_id="B3" value="60" lower_limit="23" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="05"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histology</title>
          <description>Pathology description of baseline biopsy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Papillary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Clear Cell with sarcomatoid features</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chromophobe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Translocation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG Performance Score</title>
          <description>Participants baseline ability for self-care, activity and physical ability: score 0-5. 0 is fully active. 1 is light house work and office work. 2 is cannot carry out work activities but up and about 50% of waking hours. 3 is limited to bed or chair more than 50% of waking hours 4. Completely disabled. 5. Dead</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Memorial Sloan Kettering Risk Group</title>
          <description>Score based on participants performance score, time from diagnosis to treatment, hemoglobin count, lactate dehydrogenase level, and corrected calcium levels. O score is a good prognosis. 1 -2 is an intermediate prognosis, 3-5 is a poor prognosis</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>International Metastatic RCC Database Consortium Risk Score for Renal Cell Carcinoma (RCC)</title>
          <description>Score based on participant's time from diagnosis to treatment, performance score, hemoglobin counts calcium level, neutrophil count, and platelet count. 0 is a good risk. 1-2 is an intermediate risk. 3-5 is a poor risk.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Good</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) for First Line Medication</title>
        <description>The amount of time after the first line medication begins until the cancer gets worse progresses. Progression is measured by an increase in measures tumors of at least 20 %, or overall increase in all the tumors, or the presence of new tumors.</description>
        <time_frame>7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>4 weeks of everolimus of 10 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to sunitinib.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>4 weeks of sunitinib of 50 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to everolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) for First Line Medication</title>
          <description>The amount of time after the first line medication begins until the cancer gets worse progresses. Progression is measured by an increase in measures tumors of at least 20 %, or overall increase in all the tumors, or the presence of new tumors.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" lower_limit="2.7" upper_limit="10.5"/>
                    <measurement group_id="O2" value="6.1" lower_limit="4.2" upper_limit="9.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival (PFS) for Crossover Medication</title>
        <description>The amount of time after the crossover medication begins until the cancer gets worse progresses. Progression is measured by an increase in measures tumors of at least 20 %, or overall increase in all the tumors, or the presence of new tumors.</description>
        <time_frame>4 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>4 weeks of everolimus of 10 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to sunitinib.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>4 weeks of sunitinib of 50 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to everolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) for Crossover Medication</title>
          <description>The amount of time after the crossover medication begins until the cancer gets worse progresses. Progression is measured by an increase in measures tumors of at least 20 %, or overall increase in all the tumors, or the presence of new tumors.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" lower_limit="1.4" upper_limit="10.6"/>
                    <measurement group_id="O2" value="1.8" lower_limit="1.4" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced Either a Grade 3 or 4 Adverse Event</title>
        <description>Side effects, also called adverse events, that were related to either drug were documented and graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades increases in severity from 1 - 5. Grade one is a mild change which only requires monitoring. Grade 2 is a moderate change and may require some medication. Grade 3 is severe and requires hospitalization. Grade 4 is life threatening. Grade 5 is death.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>4 weeks of everolimus of 10 mg orally each day then 2 weeks of no medication until progression.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>4 weeks of sunitinib of 50 mg orally each day then 2 weeks of no medication until progression.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced Either a Grade 3 or 4 Adverse Event</title>
          <description>Side effects, also called adverse events, that were related to either drug were documented and graded for severity according to the Common Terminology Criteria for Adverse Events (CTCAE) version 3. Grades increases in severity from 1 - 5. Grade one is a mild change which only requires monitoring. Grade 2 is a moderate change and may require some medication. Grade 3 is severe and requires hospitalization. Grade 4 is life threatening. Grade 5 is death.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival of the First Line Therapy</title>
        <description>The amount of time each participant is alive from the start of the first line therapy.</description>
        <time_frame>17 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>4 weeks of everolimus of 10 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to sunitinib.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>4 weeks of sunitinib of 50 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to everolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival of the First Line Therapy</title>
          <description>The amount of time each participant is alive from the start of the first line therapy.</description>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" lower_limit="8.0" upper_limit="23.4"/>
                    <measurement group_id="O2" value="16.2" lower_limit="14.2" upper_limit="NA">insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Best Overall Response for First Line Medication</title>
        <description>The best overall response for each participant was determined by using the Response Evaluation Criteria for Solid Tumors (RECIST). The responses are Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression Disease (PD). CR is the disappearance of the cancer everywhere in the participant. PR is at least a 30 % reduction in the measured tumors from baseline. SD is no discernible change in the presence of cancer. Progressive disease is an increase of at least 20% of the measured cancer from the cancer's smallest measure.</description>
        <time_frame>7 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Everolimus</title>
            <description>4 weeks of everolimus of 10 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to sunitinib.</description>
          </group>
          <group group_id="O2">
            <title>Sunitinib</title>
            <description>4 weeks of sunitinib of 50 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to everolimus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Best Overall Response for First Line Medication</title>
          <description>The best overall response for each participant was determined by using the Response Evaluation Criteria for Solid Tumors (RECIST). The responses are Complete Response (CR), Partial Response (PR), Stable Disease (SD), and Progression Disease (PD). CR is the disappearance of the cancer everywhere in the participant. PR is at least a 30 % reduction in the measured tumors from baseline. SD is no discernible change in the presence of cancer. Progressive disease is an increase of at least 20% of the measured cancer from the cancer's smallest measure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Cause Mortality was measure for 8 Years. Adverse events and Serious adverse events were measured for 1 year.</time_frame>
      <desc>Adverse events that were related to either medication were documented and graded for severity according to the Common Terminology Criteria of Adverse Events (CTCAE) version 3. Grades increase in severity from 1 - 5. Grade 1 is a mild change. Grade 2 is a moderate change. Grade 3 is a sever change and may require hospitalization. Grade 4 is life threatening. Grade 5 is death.</desc>
      <group_list>
        <group group_id="E1">
          <title>Everolimus</title>
          <description>4 weeks of everolimus 10 mg orally each day then 2 weeks of no medication until progression.</description>
        </group>
        <group group_id="E2">
          <title>Sunitinib</title>
          <description>4 weeks of sunitinib 50 mg orally each day then 2 weeks of no medication until progression. At progression will crossover to everolimus.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>CNS cerebrovascular ischemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Kidney Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="88" subjects_affected="33" subjects_at_risk="57"/>
                <counts group_id="E2" events="100" subjects_affected="33" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="26" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" events="112" subjects_affected="30" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" events="21" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E2" events="79" subjects_affected="32" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="33" subjects_affected="20" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Watery eye</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Watery eye</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" events="16" subjects_affected="6" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="57"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="33" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E2" events="131" subjects_affected="26" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="111" subjects_affected="36" subjects_at_risk="57"/>
                <counts group_id="E2" events="72" subjects_affected="27" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="31" subjects_affected="17" subjects_at_risk="57"/>
                <counts group_id="E2" events="115" subjects_affected="29" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="44" subjects_affected="12" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="15" subjects_affected="11" subjects_at_risk="57"/>
                <counts group_id="E2" events="50" subjects_affected="16" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="23" subjects_affected="12" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>AST</sub_title>
                <counts group_id="E1" events="33" subjects_affected="19" subjects_at_risk="57"/>
                <counts group_id="E2" events="30" subjects_affected="23" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="96" subjects_affected="33" subjects_at_risk="57"/>
                <counts group_id="E2" events="196" subjects_affected="46" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="31" subjects_affected="14" subjects_at_risk="57"/>
                <counts group_id="E2" events="44" subjects_affected="21" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypertriglyderidemia</sub_title>
                <counts group_id="E1" events="45" subjects_affected="22" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>UTI</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>ALT</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" events="21" subjects_affected="17" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="28" subjects_affected="13" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypercholestremia</sub_title>
                <counts group_id="E1" events="48" subjects_affected="27" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="37" subjects_affected="20" subjects_at_risk="57"/>
                <counts group_id="E2" events="50" subjects_affected="23" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="74" subjects_affected="31" subjects_at_risk="57"/>
                <counts group_id="E2" events="26" subjects_affected="17" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hemoglobinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="11" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="18" subjects_affected="6" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="17" subjects_affected="10" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="28" subjects_affected="11" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="78" subjects_affected="38" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Magnesuim low</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Neutrophils</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="57"/>
                <counts group_id="E2" events="79" subjects_affected="20" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" events="27" subjects_affected="25" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="57"/>
                <counts group_id="E2" events="12" subjects_affected="7" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="37" subjects_affected="15" subjects_at_risk="57"/>
                <counts group_id="E2" events="27" subjects_affected="16" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="47" subjects_affected="25" subjects_at_risk="57"/>
                <counts group_id="E2" events="33" subjects_affected="22" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="57"/>
                <counts group_id="E2" events="34" subjects_affected="17" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="25" subjects_affected="12" subjects_at_risk="57"/>
                <counts group_id="E2" events="38" subjects_affected="18" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="57"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="52" subjects_affected="19" subjects_at_risk="57"/>
                <counts group_id="E2" events="97" subjects_affected="24" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="64" subjects_affected="29" subjects_at_risk="57"/>
                <counts group_id="E2" events="53" subjects_affected="21" subjects_at_risk="51"/>
              </event>
              <event>
                <sub_title>Hand foot skin reaction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="70" subjects_affected="22" subjects_at_risk="51"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amado Zurita-Saavedra,Associate Professor, Genitourinary Medical Oncology</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>(713) 563-6966</phone>
      <email>azurita@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

